Gilead Sciences (GILD) — Profile, ISIN & Live Price

Gilead Sciences, Inc. is a prominent American biopharmaceutical company based in Foster City, California, renowned for its innovative research and development of antiviral medications. The company specializes in treatments for various viral infections, including HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. In addition to its antiviral portfolio, Gilead is also engaged in developing therapies in other critical areas such as oncology, inflammation, and cell therapy, establishing itself as a leader in the biopharmaceutical industry. The company has made significant strides in advancing HIV treatment options, exemplified by its recent collaboration with Merck, which yielded positive results from Phase 3 studies of a new oral HIV treatment.

Gilead's commitment to social responsibility is reflected in its partnerships with organizations like the National AIDS Memorial and the Gilead Foundation, aimed at enhancing HIV/AIDS education and fostering community leadership. The company actively promotes inclusivity within both the workplace and the broader community, reinforcing its dedication to diversity. As Gilead continues to expand its product offerings and strengthen its market position through strategic acquisitions and collaborations, it remains a key player in addressing global health challenges, particularly in the realm of infectious diseases and chronic conditions.